SOPHiA GENETICS (NASDAQ:SOPH) Now Covered by Analysts at Craig Hallum

Stock analysts at Craig Hallum assumed coverage on shares of SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) in a research report issued on Wednesday, MarketBeat reports. The firm set a "buy" rating and a $11.00 price target on the stock. Craig Hallum's price objective suggests a potential upside of 223.53% from the stock's previous close.

SOPHiA GENETICS Stock Performance

SOPH stock traded up $0.08 during midday trading on Wednesday, reaching $3.40. The stock had a trading volume of 44,067 shares, compared to its average volume of 62,687. The firm has a fifty day simple moving average of $3.43 and a two-hundred day simple moving average of $3.92. SOPHiA GENETICS has a 52-week low of $2.70 and a 52-week high of $7.37. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.59 and a current ratio of 3.80. The stock has a market cap of $222.28 million, a PE ratio of -3.12 and a beta of 0.99.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.04). The firm had revenue of $15.85 million during the quarter, compared to analysts' expectations of $15.90 million. SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. During the same quarter in the previous year, the business earned ($0.21) earnings per share. As a group, equities research analysts anticipate that SOPHiA GENETICS will post -0.98 EPS for the current year.

Institutional Investors Weigh In On SOPHiA GENETICS

Several hedge funds have recently bought and sold shares of SOPH. Principal Financial Group Inc. boosted its holdings in SOPHiA GENETICS by 6.3% during the third quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company's stock worth $5,290,000 after buying an additional 86,764 shares in the last quarter. Federated Hermes Inc. increased its stake in shares of SOPHiA GENETICS by 57.5% in the 2nd quarter. Federated Hermes Inc. now owns 63,000 shares of the company's stock valued at $289,000 after purchasing an additional 23,000 shares in the last quarter. Green Alpha Advisors LLC purchased a new position in shares of SOPHiA GENETICS in the 3rd quarter valued at about $79,000. Finally, Banque Cantonale Vaudoise boosted its position in SOPHiA GENETICS by 300.0% during the second quarter. Banque Cantonale Vaudoise now owns 12,000 shares of the company's stock worth $55,000 after purchasing an additional 9,000 shares in the last quarter. Hedge funds and other institutional investors own 31.59% of the company's stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.